{"acquisitions":[],"changes":[],"country":"NL","description":"Leyden Labs develops nasal sprays delivering antibodies to the respiratory mucosa to block flu, coronaviruses, and other viruses at entry. It targets at-risk groups, including the immunocompromised, and pandemic readiness. Its edge is its Mucosal Protection Platform, where low-dose intranasal antibodies stay effective as viruses mutate.","domain":"leyden-labs.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":"unknown","githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":52.159475,"lng":4.490884,"location":"Leiden","multiples":[],"name":"Leyden Labs","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":73440000,"connectionsAmong":[],"currency":"EUR","date":"2025-01-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"leyden-labs-com-2025-01-01-series-b","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-25","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"leyden-labs-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-25","status":"attributed","url":null},{"fact":"existence","publisher":"leyden-labs.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://leyden-labs.com"},{"fact":"description","publisher":"leyden-labs.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://leyden-labs.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["unknown"],"totalRaisedUsd":73440000,"traction":[],"updatedAt":"2026-05-25","valuations":[]}